Twist Bioscience beats top-line and bottom-line estimates; gives Q1 and FY2027 outlook
Twist Bioscience (TWST) reported Q4 GAAP EPS of -$0.32, beating estimates by $0.06. Revenue grew 27.9% year-over-year to $126.6M, exceeding expectations by $2.97M. The company provided fiscal 2027 revenue guidance of $550M-$560M, reflecting 21% growth at the midpoint, above the consensus of $548.67M.
How this was made
The 30-second read
Why it matters
The earnings beat and raised revenue guidance provide a fresh catalyst that could move the stock higher in early trading.
Market read
First‑report earnings and guidance lift for a micro‑cap biotech, offering a short‑term trading opportunity.
What to watch
Potential dilution from future capital raises or execution risk in scaling production.
Background
Twist Bioscience is a synthetic DNA manufacturer that recently announced its Q4 results and FY2027 outlook.
Ticker impact
Twist Bioscience reported Q4 GAAP EPS of -$0.32 beating estimates and raised FY2027 revenue guidance to $550‑$560M.
likely upside as market prices in the earnings beat and raised outlook
Both EPS and revenue topped expectations and guidance exceeds consensus, providing a clear catalyst for buying pressure.
Market effects
Biotech manufacturing sector may see modest uplift from Twist's stronger guidance.
U.S. biotech stocks could benefit in early trading.
Limited to investors tracking synthetic biology and biotech ETFs.
Counterpoint
The EPS beat is modest and still negative; skeptics may view the loss as a red flag.
Key entities
- companyTwist Bioscience
Synthetic DNA manufacturer (NASDAQ: TWST).
